Template:Fenofibrate: Difference between revisions
Jump to navigation
Jump to search
(Created page with " {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F...") |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 37: | Line 37: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Fenofibrate labels and packages|Labels and Packages]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Fenofibrate labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | TRIGLIDE <sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE dosage forms and strengths|Dosage Forms and Strengths]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE use in specific populations|Use in Specific Populations]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE clinical studies|Clinical Studies]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE how supplied storage and handling|How Supplied/Storage and Handling]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE patient counseling information|Patient Counseling Information]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[TRIGLIDE labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Fenofibrate | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Fenofibrate |